Stay updated with breaking news from Paradigm Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeuroSense Therapeutics Ltd. (NRSN) announced Tuesday that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month, randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM).
HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.